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Abstract
Summary This study showed that risedronate 150-mg once a
month provides similar efficacy and safety at 2 years com-
pared with risedronate 5-mg daily for the treatment of
postmenopausal osteoporosis. This adds to the range of
risedronate dosing options and provides an alternative for
patients who prefer once-a-month dosing.
Introduction Risedronate is effective in the treatment of
postmenopausal osteoporosis in oral daily, weekly, or on
two consecutive days per month doses. This 2-year random-
ized, double-blind, multicenter study assesses the efficacy
and safety of a single risedronate 150-mg once-a-month oral
dose compared with the 5-mg daily regimen.
Methods Women with postmenopausal osteoporosis were
randomly assigned to receive risedronate 5-mg daily
(n0642) or 150-mg once a month (n0650) for 2 years. Bone
mineral density (BMD), bone turnover markers, new vertebral
fractures, and adverse events were evaluated. The primary
efficacy endpoint was the mean percent change from baseline
in lumbar spine BMD after 1 year.
Results Four hundred ninety-eight subjects in the daily group
(77.6 %) and 513 subjects in the once-a-month group (78.9 %)
completed the study. After 24 months, the mean percent change
in lumbar spine BMD was 3.9 % (95 % confidence interval
[CI], 3.43 to 4.42%) and 4.2% (95%CI, 3.68 to 4.65%) in the
daily and once-a-month groups, respectively. The once-a-
month regimen was determined to be non-inferior to the daily
regimen. The mean percent changes in BMD at the hip were
similar in both dose groups, as were changes in biochemical
markers of bone turnover. The incidence of adverse events,
adverse events leading towithdrawal, and upper gastrointestinal
tract adverse events were similar in the two treatment groups.
Conclusions After 2 years, treatment with risedronate
150-mg once a month provided similar efficacy and
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tolerability to daily dosing and provides an alternative for
patients who prefer once-a-month oral dosing.




BALP Bone-specific alkaline phosphatase
BMD Bone mineral density
CI Confidence interval
Cr Creatinine
CTX C-terminal crosslinking telopeptide of type I
collagen
DXA Dual x-ray absorptiometry
ITT Intent to treat
MedDRA Medical Dictionary for Regulatory Activities
NTX N-terminal crosslinking telopeptide of type I
collagen
Introduction
Risedronate is a pyridinyl bisphosphonate that has been
shown in prospective studies to reduce the risk of vertebral,
nonvertebral, and hip fractures [1–3]. Like other bisphosph-
onates, risedronate remains active on the surface of bone for
long periods after dosing, providing the opportunity to
develop a range of dosing schedules.
The original risedronate dosing regimen for postmenopausal
osteoporosis was an oral dose of 5-mg daily [1–3]. It was later
demonstrated that risedronate 35-mg once a week and 75-mg
each day for two consecutive days a month provided similar
efficacy and safety to the daily regimen [4, 5]. The efficacy and
tolerability of risedronate once-a-month dosing (150-mg) was
compared with risedronate daily dosing (5-mg) in women with
osteoporosis with changes in lumbar spine bone mineral den-
sity (BMD) as the primary endpoint. After 1 year of treatment,
published previously, the efficacy of risedronate 150-mg once-
a-month regimen was non-inferior to the 5-mg daily regimen
[6]. The once-a-month regimen also had a similar tolerability
profile as the daily regimen after 1 year of treatment. This study
continued for an additional year of treatment, and the results of
the complete study over 2 years are presented here.
Materials and methods
Study design
This randomized, double-blind, active-controlled, parallel-
group non-inferiority study was conducted at 47 study cen-
ters in the Americas, Europe, Australia, and Asia
(Appendix). The first subject was screened in October
2005, and the last subject observation took place in March
2008. The study was performed in accordance with good
clinical practice and the ethical principles that have their
origin in the Declaration of Helsinki. The protocol was
approved by the appropriate institutional review boards or
ethics committees, and the subjects gave written, informed
consent to participate.
Patients
Eligible subjects who gave consent were randomly assigned in
a 1:1 ratio to the two treatment groups. Women were eligible
to enroll in the study if they were at least 50 years of age,
ambulatory, in generally good health, postmenopausal (at least
5 years since last menses), had at least three vertebral bodies in
the lumbar spine (L1 to L4) that were evaluable by densitom-
etry (i.e., without fracture or degenerative disease), and had a
lumbar spine BMD T-score of less than −2.5 or a T-score of
less than −2.0 with at least one prevalent vertebral fracture (T4
to L4). Specific details of the inclusion criteria and methods
have been previously published [6].
Treatments
Subjects received oral risedronate 5-mg daily or 150-mg
once a month (i.e., a single 150-mg tablet on the same
calendar day each month, followed by a placebo tablet daily
for the rest of the month). All tablets were identical in
appearance and supplied in identical blister cards. Tablets
were taken on an empty stomach in the morning at least
30 min before the first food or drink of the day, with at least
4 oz of plain water. Subjects were instructed to remain in an
upright position for at least 30 min after dosing. Subjects
were considered compliant if they took at least 80 % of the
study tablets. Calcium (1,000-mg/day) and vitamin D (400–
500 IU/day) were supplied to all subjects, although they
were allowed to take up to 1,000 IU/day of vitamin D. These
supplements were taken with a meal other than breakfast
and not with the study medication.
Efficacy assessments
Dual x-ray absorptiometry (DXA) measurements of the
lumbar spine and proximal femur were obtained at baseline
and after 6, 12, and 24 months using instruments manufac-
tured by Lunar Corporation (General Electric, Madison, WI,
USA) or Hologic (Waltham, MA, USA). DXA scans col-
lected at the clinical sites were sent to a central facility for
quality control and analysis (Synarc, Copenhagen/Ham-
burg). Lateral thoracic and lumbar spine radiographs col-
lected at screening and at 12 and 24 months were analyzed
for vertebral fractures by semi-quantitative analysis [7] at a
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central radiology site (Synarc, Copenhagen/Hamburg). Bio-
chemical markers of bone turnover were assessed at 3, 6, 12,
and 24 months. Serum bone-specific alkaline phosphatase
(BALP) was measured using an immunochemiluminescence
assay on an automatic analyzer (Ostase, Access, Beckman
Coulter, LaBrea, CA, USA). The intra- and interassay coef-
ficients of variation for this measurement were less than 4
and 10 %, respectively. The detection limit of the test was
0.07 ng/mL, and the limit of quantitation was 0.28 ng/mL.
Urinary N-terminal crosslinking telopeptide of type I colla-
gen (NTX) was measured with an electrochemiluminescent
immunoassay on an automated machine (Vitros ECi, John-
son and Johnson, Rochester, NY, USA). The intra- and
interassay coefficients of variation were below 7 and 6 %,
respectively. The detection limit of the test was 4 nM, and
the limit of quantitation was 22 nM. This measurement was
corrected for creatinine (NTX/Cr). Serum C-terminal cross-
linking telopeptide of type I collagen (CTX) was measured
using an enzyme immunoassay kit (Serum CrossLaps®,
Nordic Bioscience Diagnostics, Herlev, Denmark). The
intra- and interassay coefficients of variation were below
8 and 6 %, respectively. The lower limit of detection was
0.044 ng/mL. Bone turnover marker assays were performed
at a central laboratory (Synarc SAS, Lyon, France). The
samples for the 24-month study visit were measured at a
different time than the samples for all previous visits.
Safety assessments
Physical examinations were performed at baseline and after
12 and 24 months. Vital signs, concomitant medications,
and adverse event reports were recorded at regular clinic
visits throughout the study. Adverse event reports were
captured using the Medical Dictionary for Regulatory Ac-
tivities (MedDRA) system. Blood and urine samples for
clinical chemistry and other standard laboratory measure-
ments were collected at baseline and after 3, 6, 9, 12, 18, and
24 months of treatment. Specimens were analyzed by
Quintiles Laboratories (Smyrna, GA, USA).
Statistical analysis
The primary endpoint analysis was a test of non-inferiority
comparing the least squares mean percent change from
baseline in lumbar spine BMD in the 150-mg once-a-
month and 5-mg daily groups after 12 months. This test
employed a predefined non-inferiority margin of 1.5 % and
a one-sided type I error of 2.5 %. The results of this analysis
have been published previously [6].
Secondary endpoints included the percent change from
baseline in lumbar spine BMD at months 6 and 24, and at
endpoint; the percent change from baseline in BMD of the
total proximal femur, femoral neck, and femoral trochanter
at months 6, 12, and 24, and at endpoint; the percentage of
patients with new vertebral fractures at year 1 and 2; and the
percent change from baseline in biochemical markers of
bone turnover (NTX/Cr, CTX, and BALP) at months 3, 6,
12, and 24, and at endpoint. All data reported here are based
upon cumulative data collected over the entire 2-year
treatment period.
After 2 years of treatment, a non-inferiority analysis was
performed based on the one-sided 97.5 % confidence inter-
val (CI) for the difference in mean percent change from
baseline to month 24 in lumbar spine BMD. The CIs were
constructed using an ANOVA model with fixed effects for
treatment and pooled investigative center. If the upper
bound of the 97.5 % one-sided CI did not exceed 2.0 %,
then the once-a-month treatment was considered non-
inferior to the daily treatment. This analysis was based on
all subjects who were randomized and took at least one dose
of study medication and who had evaluable lumbar spine
BMD measurements at both baseline and at least one post-
baseline time point (last observation carried forward; this is
the intent-to-treat [ITT] population). The month 24 non-
inferiority “delta” was selected using the same rationale
used to select the month 12 non-inferiority margin. In pre-
vious studies contrasting risedronate 5-mg daily and placebo
for the treatment of postmenopausal osteoporosis, the mean
percent change difference between the treatment groups in
lumbar spine BMD from baseline to month 24 ranged from
4.1 to 5.4 %. Thus, using a “delta” of 2.0 % would maintain
approximately 50 % of the effect size of the risedronate
5-mg daily dose relative to placebo at month 24.
The treatment group differences at month 24 in percent
changes in proximal femur BMD and bone turnover markers
were analyzed using an ANOVAmodel; two-sided 95 % CIs
for the treatment differences were constructed using the ITT
population. The incidence of new vertebral fractures over
24 months was analyzed using Fisher's exact test. Adverse
events were summarized as frequency distribution tables
and reported by treatment group.
Results
Subjects
From the total of 2,221 women who were screened, 1,294
subjects were randomized, and 1,292 subjects received at
least one dose of study drug (Fig. 1). Overall, baseline
characteristics were similar in both treatment groups. De-
mographics of the subjects in each treatment group have
been reported previously [6]. A similar percentage of sub-
jects in each treatment group completed 24 months of the
study (5-mg daily group, 77.6 %; 150-mg once-a-month
group, 78.9 %). The most common reasons given for
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withdrawal during year 2 were adverse event and voluntary
withdrawal, which occurred at similar incidences in both
treatment groups. A high percentage of subjects in both
groups (95.5 % of subjects in the 5-mg daily group and
95.7 % of subjects in the 150-mg once-a-month group) took
at least 80 % of the study tablets.
Efficacy assessments
The within-group mean percent changes from baseline in
lumbar spine BMD were statistically significant in both
treatment groups at each time point (Fig. 2). The mean
percent changes at 24 months (95 % CI) were 3.9 % (3.43
to 4.42 %) for the 5-mg daily group and 4.2 % (3.68 to
4.65 %) for the 150-mg once-a-month group. The difference
from the 5-mg daily group (daily minus once a month) in
mean percent change from baseline in lumbar spine BMD at
month 24 was –0.24 % (95 % upper confidence bound,
0.25 %). This upper boundary was well below the 2.0 %
needed to establish non-inferiority; thus, the 150-mg once-a-
month regimen was determined to be non-inferior to the 5-mg
daily regimen at 24 months. Significant increases from base-
line in BMD were observed at 6, 12, and 24 months in both
treatment groups (Fig. 2). There was no statistically significant
difference between treatment groups in mean percent change
in BMD at the lumbar spine or regions of the proximal femur
(total proximal femur, femoral neck, and femoral trochanter)
at any time point.
There was no difference between treatment groups in the
occurrence of new incident vertebral fracture as determined by
morphometric measurement during the study; 14 subjects
(2.5 %) in the 5-mg daily group and 15 subjects (2.6 %) in
the 150-mg once-a-month group experienced such a fracture.
Significant decreases from baseline in NTX/Cr, CTX,
and BALP were observed at 3, 6, 12, and 24 months in both
treatment groups (Fig. 3). In general, changes from baseline
in these biochemical markers were similar in both treatment
groups. The small difference in CTX between groups was
statistically significant at months 3, 6, and 12 but not at
month 24. There was no statistically significant difference
between treatment groups at endpoint (the last-observation-
carried forward values at month 24) for any of the
biochemical markers of bone turnover.
Safety assessments
Overall, the frequency of adverse events was similar in both
treatment groups (Table 1). Among the most common ad-
verse events, only diarrhea and influenza were more fre-
quent in the monthly group compared with the daily group
after 24 months. The difference between groups in these
adverse events was primarily driven by events reported
during the first few months of the study. Most events of
diarrhea were mild or moderate in severity. One subject
(0.2 %) in the 5-mg daily group and six subjects (0.9 %)
in the 150-mg once-a-month group withdrew from the study
as a result of diarrhea. All events of influenza were mild or
moderate in severity, most occurred more than 90 days after
the start of treatment, and none of the subjects withdrew
because of influenza. More patients in the 150-mg once-a-
Screen failures:
  Did not meet BMD criteria (n = 524)
  Did not meet lab criteria (n = 167)
  Did not consent to continue (n = 153)












risedronate 150-mg once a month
(n = 650)
Completed 1 year of treatment
(n = 538)
Completed 1 year of treatment
(n = 556)
Withdrawn:
  Due to adverse event (n = 25)
  Voluntary (n = 9) 
  Other  (n = 6)
Withdrawn:
  Due to adverse event  (n = 26)
  Voluntary (n = 11)
  Other  (n = 6)
Completed 2 years of treatment
(n = 498)
Completed 2 years of treatment
(n = 513)
Fig. 1 Disposition of subjects.
BMD bone mineral density











































































































Fig. 2 Mean percent change
(±SEM) from baseline in bone
mineral density in women
receiving risedronate 5-mg daily
(dashed line with triangles) or
150-mg once a month (solid line
with circles). Endpoint refers to
the value calculated using the
last observation carried forward
at month 24. There were no
statistically significant
differences between treatment
groups at any time point at any



























































































Fig. 3 Mean percent change (±SEM) from baseline in biochemical
markers of bone turnover in women receiving risedronate 5-mg daily
(dashed line with triangles) or 150-mg once a month (solid line with
circles). Endpoint refers to the value calculated using the last observa-
tion carried forward at month 24. CTX C-terminal crosslinking
telopeptide of type I collagen, NTX N-terminal crosslinking telopeptide
of type I collagen, OAM once a month. *p<0.05 indicates a statistically
significant difference between treatment groups (unadjusted for multi-
ple comparisons)
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month group reported serious adverse events than in the
5-mg daily group (Table 1). This difference was pre-
dominantly due to small differences between the two
groups in several MedDRA System Organ Class cate-
gories, and none of the differences in any of the indi-
vidual System Organ Class categories reached statistical
significance.
Adverse events of special interest for bisphosphonates
(clinical vertebral and nonvertebral fractures, upper gastro-
intestinal tract adverse events, and musculoskeletal adverse
events) were reported by similar proportions of subjects in
both treatment groups (Table 1). The incidence of atrial
fibrillation reported as either an adverse event or a serious
adverse event was low and similar between groups (Table 1).
There were no reported cases of osteonecrosis of the jaw.
The number of subjects who developed a neoplasm did not
differ by treatment group (Table 1). Results of clinical
chemistry and other laboratory measurements, including
measures of hepatic and renal function, were similar in both
treatment groups.
Discussion
Risedronate is a widely used osteoporosis treatment with
proven vertebral and nonvertebral antifracture efficacy and a
minimum wait of 30 min after dosing before eating or drink-
ing anything other than water. A 5-mg daily regimen was
developed originally, but less frequent dose regimens have
now been developed. This study was a preplanned 2-year
study comparing a dose of risedronate 150-mg once a month
to the 5-mg daily dose. These 2-year data show that the
150-mg once-a-month dose continues to produce clinical
effects that are similar to those seen with the 5-mg daily dose.
Specifically, the mean percent change in lumbar spine BMD at
24 months in the monthly group was non-inferior to the mean
percent change in lumbar spine BMD in the daily group.
Changes in secondary efficacy parameters, including BMD
at the hip, bone turnover markers at endpoint, and morpho-
metric vertebral fractures, were also similar in both groups.
Statistically significant differences between treatment groups
were observed for all three bone turnover markers at month 3,
but persisted at months 6 and 12 for CTX only. No statistically
significant differences between groups were observed for any
marker at month 24 or endpoint. That the CTX response did
not differ between treatment groups at month 24 might be
explained by the small number of subjects at month 24 that
would limit statistical power to observe difference. It is not
likely that these small differences between groups in bone
turnover markers are clinically meaningful.
The risedronate 150-mg once-a-month dose was well
tolerated over 2 years, with a safety profile similar to that
seen with the 5-mg daily regimen. The low incidences of
subjects with vertebral and nonvertebral clinical fractures
were similar between groups and consistent with rates
previously observed with the 5-mg daily dose [1–3].
Change in BMD is an appropriate endpoint when evalu-
ating a new dosing schedule of a bisphosphonate for which a
fracture benefit has already been established. Similar non-
inferiority trials have been conducted previously to evaluate
new dosing regimens of oral bisphosphonates [4, 8, 9], and
this approach has been accepted by both the US Food and
Drug Administration and the European Medicines Agency
[10] for approval of new regimens of established agents.
The magnitude of BMD change associated with the verte-
bral and nonvertebral antifracture efficacy of risedronate has
been established in multiple large studies that had fracture as
the primary endpoint [1–3]. This study has demonstrated
that the 150-mg once-a-month dose reduces bone turnover
and increases BMD to a degree comparable to that observed
with the 5-mg daily dose in these fracture studies.
The results of this study after 2 years are consistent with the
findings at month 12 [6], demonstrating the persistent simi-
larity between risedronate 150-mg once-a-month and the
5-mg daily dosing regimens. Additionally, these results are
Table 1 Summary of adverse events
Risedronate
5-mg daily 150-mg once a month
(N0642) (N0650)
n (%) n (%)
AEs 554 (86.3) 578 (88.9)
Serious AEs 51 (7.9) 77 (11.8)
Deaths 4 (0.6) 0
Withdrawn due to an AE 84 (13.1) 80 (12.3)
Most common AE associated with withdrawal
Gastrointestinal disorder 49 (7.6) 47 (7.2)
Most common AEs
Influenza 57 (8.9) 94 (14.5)
Nasopharyngitis 62 (9.7) 70 (10.8)
Diarrhea 43 (6.7) 69 (10.6)
Arthralgia 68 (10.6) 65 (10.0)
Back pain 80 (12.5) 65 (10.0)
Bronchitis 68 (10.6) 57 (8.8)
AEs of special interest
Clinical vertebral fracture 6 (0.9) 4 (0.6)
Nonvertebral fracture 25 (3.9) 28 (4.3)
Upper gastrointestinal tract AEs 148 (23.1) 169 (26.0)
Selected musculoskeletal AEsa 172 (26.8) 163 (25.1)
Atrial fibrillation 1 (0.2) 3 (0.5)
Neoplasmsb 23 (3.6) 25 (3.8)
a Includes arthralgia, back pain, bone pain, musculoskeletal pain, mus-
culoskeletal discomfort, myalgia, and neck pain
b Includes benign and malignant neoplasms, polyps, and cysts
AE adverse event
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consistent with the favorable tolerability and efficacy profiles
observed in large placebo-controlled clinical trials of the
risedronate 5-mg daily regimen [1–3]. The findings are also
consistent with previous studies of less frequent dosing with
risedronate. Such studies showed that the treatment effects of
risedronate 35-mg weekly and 75-mg on two consecutive days
each month were similar to the effects of daily dosing [4, 5].
Risedronate 150-mg once a month, taken for 2 years, is
similar in efficacy and tolerability to the 5-mg daily dosing
regimen that had been proven to reduce the incidence of
vertebral and nonvertebral fractures. The addition of this dosing
regimen to the therapeutic armamentariumwill provide women
with postmenopausal osteoporosis a full range of risedronate
oral dosing options, from daily to weekly to monthly.
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